James Randolph Hillard
Chairman at Phase 2 Discovery, Inc.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Ronald Brown | M | 70 |
University of Cincinnati (Ohio)
| 11 years |
| J. Schlotman | M | 66 |
University of Cincinnati (Ohio)
| - |
| Tao Sheng Huang | M | 62 |
University of Cincinnati (Ohio)
| - |
| Robert Ludke | M | - |
University of Cincinnati (Ohio)
| - |
| Ihab M. Hamdi Saad | M | - |
University of Cincinnati (Ohio)
| - |
| Santa Ono | M | - |
University of Cincinnati (Ohio)
| - |
| Awatef Hamed | M | - |
University of Cincinnati (Ohio)
| - |
| Daniel Acosta | M | - |
University of Cincinnati (Ohio)
| - |
| Hagit Limor Sunberg | F | - |
University of Cincinnati (Ohio)
| - |
| Jason Charles Heikenfeld | M | - |
University of Cincinnati (Ohio)
| - |
| Daniel von Allmen | M | - |
University of Cincinnati (Ohio)
| 15 years |
| Don Wathen | M | - |
University of Cincinnati (Ohio)
| 13 years |
| William H. Wilson | M | - |
University of Cincinnati (Ohio)
| - |
| Bob Arkeilpane | M | - |
University of Cincinnati (Ohio)
| - |
| Bogdan Vykhovanyuk | M | - |
University of Cincinnati (Ohio)
| - |
| Marianne Lewis | F | - |
University of Cincinnati (Ohio)
| - |
| Timothy Jachna | M | - |
University of Cincinnati (Ohio)
| - |
| Melanie Kroger-Jarvis | F | - |
University of Cincinnati (Ohio)
| - |
| Alberto Jones | M | - |
University of Cincinnati (Ohio)
| - |
| Valerio Ferme | M | - |
University of Cincinnati (Ohio)
| - |
| Carl Dieso | M | - |
University of Cincinnati (Ohio)
| - |
| Victor E. Schwartz | M | - |
University of Cincinnati (Ohio)
| - |
| Stephanie Parrish | F | - |
University of Cincinnati (Ohio)
| - |
| Glenn Grismere | M | - |
University of Cincinnati (Ohio)
| - |
| Thomas Finn | M | 63 |
University of Cincinnati (Ohio)
| - |
| Joseph A. Steger | M | 87 |
University of Cincinnati (Ohio)
| - |
| Phillip Cox | M | 76 |
University of Cincinnati (Ohio)
| - |
| George Schaefer | M | 78 |
University of Cincinnati (Ohio)
| - |
| Mark R. White | M | - |
University of Cincinnati (Ohio)
| - |
| Robert Jerome Chapman | M | 77 |
University of Cincinnati (Ohio)
| - |
| John B. Harley | M | 74 |
University of Cincinnati (Ohio)
| 14 years |
| Frederick A. Russ | M | 79 |
University of Cincinnati (Ohio)
| 35 years |
| Karl Scheer | M | - |
University of Cincinnati (Ohio)
| 13 years |
| Richard C. Levy | M | 77 |
University of Cincinnati (Ohio)
| 40 years |
| Timothy Johnson | M | 81 |
University of Cincinnati (Ohio)
| 54 years |
| Salvatore Privitera | M | 57 |
University of Cincinnati (Ohio)
| - |
| Ronald A. Khan | M | - |
University of Cincinnati (Ohio)
| - |
| Frank P. Zemlan | M | - |
Phase 2 Discovery, Inc.
 Phase 2 Discovery, Inc. Pharmaceuticals: MajorHealth Technology Phase 2 Discovery, Inc. (P2D) develops central nervous system drugs. The company provides discovery research & development services for pharmaceutical and biotechnology companies. It also develops drugs for treating psychiatric and neurologic disorders. Its products include PD6735, the treatment of primary insomnia and additional indications, N-Substituted Analogs of Benztropine for the treatment of attention deficit hyperactivity disorder & Thiothalidomides and Hydroxythalidomides for the treatment of ALS and MS. Phase 2 Discovery was founded in 1998 and is headquartered in Cincinnati, OH. | - |
| Thomas D. Geracioti | M | - |
Phase 2 Discovery, Inc.
Phase 2 Discovery, Inc. Pharmaceuticals: MajorHealth Technology Phase 2 Discovery, Inc. (P2D) develops central nervous system drugs. The company provides discovery research & development services for pharmaceutical and biotechnology companies. It also develops drugs for treating psychiatric and neurologic disorders. Its products include PD6735, the treatment of primary insomnia and additional indications, N-Substituted Analogs of Benztropine for the treatment of attention deficit hyperactivity disorder & Thiothalidomides and Hydroxythalidomides for the treatment of ALS and MS. Phase 2 Discovery was founded in 1998 and is headquartered in Cincinnati, OH. | - |
| John M. Tew | M | - |
University of Cincinnati (Ohio)
| - |
| Andrew Robell | M | - |
Phase 2 Discovery, Inc.
Phase 2 Discovery, Inc. Pharmaceuticals: MajorHealth Technology Phase 2 Discovery, Inc. (P2D) develops central nervous system drugs. The company provides discovery research & development services for pharmaceutical and biotechnology companies. It also develops drugs for treating psychiatric and neurologic disorders. Its products include PD6735, the treatment of primary insomnia and additional indications, N-Substituted Analogs of Benztropine for the treatment of attention deficit hyperactivity disorder & Thiothalidomides and Hydroxythalidomides for the treatment of ALS and MS. Phase 2 Discovery was founded in 1998 and is headquartered in Cincinnati, OH. | - |
| James Jeffery Mulchahey | M | - |
Phase 2 Discovery, Inc.
Phase 2 Discovery, Inc. Pharmaceuticals: MajorHealth Technology Phase 2 Discovery, Inc. (P2D) develops central nervous system drugs. The company provides discovery research & development services for pharmaceutical and biotechnology companies. It also develops drugs for treating psychiatric and neurologic disorders. Its products include PD6735, the treatment of primary insomnia and additional indications, N-Substituted Analogs of Benztropine for the treatment of attention deficit hyperactivity disorder & Thiothalidomides and Hydroxythalidomides for the treatment of ALS and MS. Phase 2 Discovery was founded in 1998 and is headquartered in Cincinnati, OH. | - |
| Eli M. Roth | M | - |
University of Cincinnati (Ohio)
| - |
| James Holloman | M | 69 |
University of Cincinnati (Ohio)
| - |
| Peter Disimile | M | - |
University of Cincinnati (Ohio)
| - |
Connections Chart
Multi-company connection
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 45 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- James Randolph Hillard
- Personal Network
